[Memantine: from the original brand to generics].

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Glutamate excitotoxicity is implicated in neurodegenerative disorders like Alzheimer's disease (AD).
• Memantine is a clinically available N-methyl-D-aspartate (NMDA) receptor antagonist.
• Memantine offers a novel approach to counteract excitotoxicity in AD.

Purpose of the Study:

• To evaluate the efficacy and tolerability of memantine in moderate to severe Alzheimer's disease.
• To assess the real-world effectiveness of the generic memantine drug Noojerone in Russia.
• To determine the impact of generic memantine on patient compliance and caregiver burden.

Main Methods:

• Clinical studies assessing memantine's effects on cognition, mood, behavior, and daily living activities.
• Postmarketing surveillance of Noojerone in a real-life clinical setting.
• Analysis of treatment tolerability, side-effect profiles, and patient compliance.

Main Results:

• Memantine (20 mg) demonstrates positive effects on cognitive and behavioral functions in moderate to severe AD.
• Noojerone provides long-term, effective therapy for moderate and severe Alzheimer's dementia.
• Noojerone shows significant therapeutic effects on cognitive function, daily living, behavioral symptoms, and reduces caregiver burden.
• Generic memantine is well-tolerated, affordable, and improves treatment compliance.

Conclusions:

• Memantine is an effective treatment for moderate to severe Alzheimer's disease.
• Generic memantine, such as Noojerone, is a viable, affordable, and well-tolerated therapeutic option.
• Noojerone improves patient outcomes and reduces the burden on caregivers for Alzheimer's dementia.